Swiss govt COVID-19 vaccine purchase plan fails to pass parliament

17 June 2022

The Swiss parliament has failed to finance the government's plan to buy COVID-19 vaccines in 2023, forcing the cabinet to try to renegotiate contracts with Moderna (Nasdaq: MRNA) and Pfizer (NYSE: PFE)/BioNTech’s (Nasdaq: BNTX) for millions of doses of their vaccines, according to a report from Reuters. The vaccines are marketed as Spikevax and Comirnaty, respectively.

With the two houses of parliament split over the funding request, budget rules required the adoption of the cheaper version of draft legislation, the SDA news agency said.

Parliament approved spending 560 million Swiss francs ($579 million) instead of the requested 780 million francs. That means the government could initially procure only 3.5 million additional vaccine doses each from Moderna and Pfizer/Biontech instead of 7 million each for 2023 it announced in March, Reuters noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK